China's Kangtai starts mid-stage trial of its COVID-19 vaccine candidate

By Reuters

China's Shenzhen Kangtai Biological Products has begun a mid-stage human trial of its experimental coronavirus vaccine, clinical trial registry data shows. Kangtai's candidate is among more than 10 potential vaccines Chinese scientists have brought into various phases of clinical trials in efforts to counter the virus that has killed more than 1.1 million people globally. The company plans to test the vaccine's safety and ability to trigger immune responses in a Phase 2 clinical trial expected to recruit 1,000 participants, according to the latest record published on the Chinese Clinical Trial Registry on Wednesday.

…read more

Via:: Sports Headlines

      

Get 20% off hat purchases for ONLY $5! Join our LIDS Club @ lids.com.
%d bloggers like this: